NCT02522130

Brief Summary

Different ways of reducing pain during IUD insertion have been explored. So a randomized study will be conducted to test their role

Trial Health

47
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2015

Geographic Reach
2 countries

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

July 8, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 13, 2015

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

June 22, 2016

Status Verified

June 1, 2016

Enrollment Period

1.4 years

First QC Date

July 8, 2015

Last Update Submit

June 21, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • current pain level with IUD insertion and 15 minutes post procedure measured by the Visual Analogue Scale.

    A Visual Analogue Scale is a measurement instrument that tries to measure a characteristic or attitude that is believed to range to across a continuum of values and can not easily to be directly measured. Subjects pain using a 10 point visual analogue scale (-+VAS, anchors: 0=non, 10 = worst imaginable). The participants were asked to mark their pre IUD insertion pain expectancies initially, then to mark their pain during different steps of IUD placement.

    15 minutes

Study Arms (4)

lidocaine group

ACTIVE COMPARATOR

Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,

Drug: Lidocaine

misoprostol group

ACTIVE COMPARATOR

Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion

Drug: oral misoprostol

non steroid group

ACTIVE COMPARATOR

Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion

Drug: naproxen

placebo group

PLACEBO COMPARATOR

group D will receive placebo tablets.

Other: placebo

Interventions

intracervical injection

lidocaine group

oral treatment

misoprostol group

oral treatment

non steroid group
placeboOTHER

oral treatment

placebo group

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients are considered eligible if:
  • they are alert oriented and co-operative to response to the visual analogue scale (VAS).
  • They will sign the informed consent to participate in the clinical trial before entering the study.
  • Willingness to be randomized and complete study questionnaires.

You may not qualify if:

  • Participants are excluded from participation if they are ineligible for an IUD by accepted criteria of our institution such as:
  • A lidocaine allergy
  • Copper allergy
  • Current cervicitis
  • Pelvic inflammatory disease (PID) within 3 months
  • Uterine anomalies
  • Pain medication within 6 hours before insertion
  • Misoprostol administration within 24 hour before insertion
  • History of cervical surgery and contraindication to study medications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Menoufia University

Shebin Elkom, Egypt

RECRUITING

Alhayah national hospital

Abhā, Saudi Arabia

RECRUITING

MeSH Terms

Interventions

LidocaineMisoprostolNaproxen

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesProstaglandins E, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological FactorsNaphthaleneacetic AcidsNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

July 8, 2015

First Posted

August 13, 2015

Study Start

July 1, 2015

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

June 22, 2016

Record last verified: 2016-06

Locations